Clinical Trial Update: MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating MaaT013 as salvage therapy for ruxolitinib-refractory gastrointestinal acute graft-versus-host disease; the study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Steroid-refractory Graft-versus-host Disease

Drugs mentioned

• MaaT013

Snippet

Sponsor: MaaT Pharma | Conditions: Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD | Phase 3 | Status: ACTIVE_NOT_RECRUITING